FULVESTRANT
Metastatic Malignant Neoplasm in the Brain
Nationwide Children's HospitalSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Metastatic Malignant Neoplasm in the Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Copper Cu 64-DOTA-Trastuzumab City of Hope Medical Center | Phase 4 | BB |
Namenda NRG Oncology | Phase 3 | BB |
CARVEDILOL SWOG Cancer Research Network | Phase 3 | B |
Atezolizumab National Cancer Institute (NCI) | Phase 2 | B |
Memantine Hydrochloride NRG Oncology | Phase 3 | B |
View all 30 →
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →